Circulating tumor cells and emerging blood biomarkers in breast cancer

Criscitiello, Carmen; Sotiriou, Christos; Ignatiadis, Michail

doi:10.1097/cco.0b013e32833de186

Cited by 47 publications

(30 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By screening the expression levels of 754 human miRs using miR arrays in 16 breast tumor samples from 8 cases with local recurrence and 8 cases without local recurrence, Zhou and his colleagues reported that microRNA-9 could be used as a potential biomarker for breast cancer local recurrence and tumor estrogen receptor status [33]. As the stability of miRs and their detection in circulation, the miRNAs in body fluids, such as serum and plasma, open up the possibility of using them as noninvasive biomarkers in breast cancer [34,35]. MiR-497, identified from the microRNA cluster site at chromosome 17p13.1, has been reported to function as a tumor suppressor in a variety of human cancers, including non-small cell lung cancer, hepatocelluar cancer, neroblastoma, colorectal cancer and breast cancer [18,21,36-38].…”

Section: Discussionmentioning

confidence: 99%

RETRACTED ARTICLE: Expression of microRNA-497 and its prognostic significance in human breast cancer

Wang

et al. 2013

Diagn Pathol

View full text Add to dashboard Cite

ObjectiveDysregulation of microRNAs (miRNAs) plays critical roles in tumor progression. The aim of this study was to investigate the clinicopathologic and prognostic significance of miR-497 expression in human breast cancer (BC).MethodsTaqman qRT-PCR assay was performed to detect the expression of microRNA (miR)-497 in 30 pairs of BC tissues and corresponding noncancerous breast tissues. Additionally, the expression of this miRNA was detected in another 128 BC tissues and its correlations with clinicopathologic features of patients were analyzed. Kaplan-Meier analyses were used to assess survival of patients. Univariate and multivariate analyses were performed using the Cox proportional hazards model to analyze the prognostic significance of miR-497 expression.ResultsOur data indicated that the relative level of miR-497 expression in BC tissues was significantly lower than that in corresponding noncancerous breast tissues (P = 0.0046). Of 128 BC patients, 74 (57.8%) were placed in the high-miR-497 group and 54 (42.2%) were placed in the low-miR-497 group. By statistical analyses, low miR-497 expression was observed to be closely correlated with higher differentiation grade, positive HER-2 expression, higher incidence of lymph node metastasis and advanced clinical stage. Moreover, patients with high miR-497 expression had better 5-year disease-free and overall survival compared with the low miR-497 group (P = 0.0124 and 0.0018, respectively). Univariate and multivariate analyses indicated that low miR-497 expression was an independent poor prognostic factor for BC patients.ConclusionsOur data provided the first evidence that downregulation of miR-497 was correlated with BC progression, and miR-497 might be a potential molecular biomarker for predicting the prognosis of patients.Virtual slidesThe virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2025828761093488

show abstract

Section: Discussionmentioning

confidence: 99%

RETRACTED ARTICLE: Expression of microRNA-497 and its prognostic significance in human breast cancer

Wang

et al. 2013

Diagn Pathol

View full text Add to dashboard Cite

show abstract

“…Together with the reported strong overexpression of TROP2 on metastatic tumor cells, studies should include anti-TROP2 stainings to detect and quantify circulating tumor cells; this strategy currently mostly relies on anti-EpCAM stainings (Criscitiello et al, 2010).…”

Section: Discussionmentioning

confidence: 99%

Identification of TROP2 (TACSTD2), an EpCAM-Like Molecule, as a Specific Marker for TGF-β1-Dependent Human Epidermal Langerhans Cells

Eisenwort

Jurkin

Yasmin

et al. 2011

Journal of Investigative Dermatology

View full text Add to dashboard Cite

Langerin (CD207) expression is a hallmark of epidermal Langerhans cells (LCs); however, CD207(+) cells comprise several functional subsets. Murine studies showed that epidermal, but not dermal, CD207(+) cells require transforming growth factor-β 1 (TGF-β1) for development, whereas human data are lacking. Using gene profiling, we found that the surface molecule TROP2 (TACSTD2) is strongly and rapidly induced during TGF-β1-dependent LC commitment of human CD34(+) hematopoietic progenitor cells or monocytes. TROP2 is conserved between mouse and human, and shares substantial amino-acid identity with EpCAM, a marker for murine epidermal LCs. To our knowledge, neither TROP2 nor EpCAM expression has been analyzed in human dendritic cell (DC) subsets. We found that (i) all human epidermal LCs are TROP2(+)EpCAM(+); (ii) human dermis lacks CD207(+)EpCAM(-) or CD207(+)TROP2(-) DCs, i.e., equivalents of murine dermal CD207(+) DCs; and (iii) pulmonary CD207(+) cells are TROP2(-)EpCAM(-). Moreover, although EpCAM was broadly expressed by pulmonary and intestinal epithelial cells, as well as by bone marrow erythroid progenitor cells, these cells lacked TROP2. However, although TROP2 is expressed by human LCs as well as by human and murine keratinocytes, most murine LCs, except of a small subset, lacked TROP2. Therefore, TROP2 is a marker for human TGF-β1-dependent epidermal LCs.

show abstract

“…Kidney cancer cells may escape detection by surface marker-based methods, such as those based on epithelial cell adhesion molecule (EpCAM). 22 The conundrum of surface marker-based detection is especially conspicuous in kidney cancer, which is of mesodermal origin and expresses intrinsically low or no EpCAM. A number of other cancer types, including transitional cell carcinoma of the urinary bladder, squamous carcinoma of the skin, and hepatocellular carcinoma, have been known to express little EpCAM.…”

Section: Discussionmentioning

confidence: 99%

Optical Imaging of Kidney Cancer with Novel Near Infrared Heptamethine Carbocyanine Fluorescent Dyes

et al. 2013

View full text Add to dashboard Cite

PURPOSE To assess the application of near-infrared (NIR) heptamethine carbocyanine dyes, IR-783 and the synthetic analog MHI-148, as optical imaging agents for rapid detection of human kidney cancer. MATERIALS AND METHODS The uptake, retention and subcellular localization of these organic dyes were investigated in cultured kidney cancer cells. Tumor specificity of dye uptake and retention was evaluated by whole-body imaging of mice bearing human kidney cancer xenografts or freshly harvested clinical kidney cancer specimens. In addition, dye accumulation at the tissue and cellular levels was confirmed by ex vivo studies with results confirmed by fluorescence imaging of the frozen tissue sections. Peripheral blood spiked with kidney cancer cells was stained to simulate the detection of circulating tumor cells. RESULTS Preferential uptake and retention of carbocyanine NIR dyes was observed in cultured human kidney cancer cells, human kidney cancer cell-spiked whole blood, human kidney cancer xenografts and freshly harvested human kidney cancer tissues compared to normal kidney epithelial cells or normal host organs. CONCLUSIONS We described a new class of NIR heptamethine carbocyanine dyes showing potential for detecting kidney cancer cells in circulating blood and kidney cancer cells in clinical specimens. NIR carbocyanine dyes can be further developed as dual modality agents for deep-tissue imaging of localized and disseminated kidney cancer in patients.

show abstract

Circulating tumor cells and emerging blood biomarkers in breast cancer

Abstract: Currently, there is no role for CTCs in clinical practice. The clinical utility of CTCs and other blood biomarkers should be prospectively tested.

Cited by 47 publications

References 47 publications

RETRACTED ARTICLE: Expression of microRNA-497 and its prognostic significance in human breast cancer

RETRACTED ARTICLE: Expression of microRNA-497 and its prognostic significance in human breast cancer

Identification of TROP2 (TACSTD2), an EpCAM-Like Molecule, as a Specific Marker for TGF-β1-Dependent Human Epidermal Langerhans Cells

Optical Imaging of Kidney Cancer with Novel Near Infrared Heptamethine Carbocyanine Fluorescent Dyes

Contact Info

Product

Resources

About